Molence· @MolenceBio · X·· 17 天前AI 评分55
AI 导读
Molence Bio 报告,在 4-1BB 靶点上用第一轮实验结果指导第二轮设计,功能性命中由第一轮的 30 个中 2 个(7%)提升到第二轮的 60 个中 51 个(85%)。在 0.03 nM 浓度下,这 51 个二轮激动剂中有 48 个超过 Utomilumab 阳性对照的平均激活水平。公司表示,这些 VHH-Fc 结果说明实验反馈可以扩大功能性设计的候选池。
正文 · 原文
5/15 🔁 One round of experimental feedback. A functional hit rate of 7% → 85%.
For 4-1BB, we used first-round experimental results to guide a second design round:
• Round 1: 2/30 functional hits
• Round 2: 51/60 functional hits
At 0.03 nM, 48 of the 51 second-round agonists exceeded the mean activation of the Utomilumab positive control.
These VHH-Fc results show how experimental feedback can expand the pool of functional designs.
#ProteinDesign
4/15 🎯 43 pM affinity from zero-shot BCMA designs. Thirty designs yielded 12 binding hits. Two selected candidates, tested as VHH-Fc fusions, achieved SPR KD values of 43 pM and 1.1 nM. They also bound cell-surface BCMA: EC50 values were 0.19 and 0.16 nM, versus 4.1 nM for the belantamab biosimilar in the same assay. High-affinity recognition modules for further engineering into multivalent and multispecific antibody formats. #ProteinDesign在 X 查看被引用的帖子
来源:Molence · x.com